FAST BioMedical Aims to Quantify Volume Status and Revolutionize Heart Failure Treatment
Heart failure affects 6.5 million adults in the United States (CDC), leading to more than 1 million primary hospitalizations in the country. FAST BioMedical (FBM) is developing medical technology to measure a patient’s intravascular volume status and kidney function with the aim to revolutionize the treatment of patients suffering from heart failure. Today, standard of care for assessing a patient’s volume status or kidney function are estimates. FBM’s technology has the potential to dramatically improve heart failure patient management by measuring – rather than estimating – both volume status and kidney function.
FBM’s first-in-class technology is being developed to offer a direct, dynamic, serial measurement of volume status and kidney function, which can potentially give a clearer clinical picture to improve fluid management for heart failure patients. Other technologies that can measure volume status or kidney function can only measure one at a time and require cumbersome and expensive tools. FBM measures these indicators quickly and easily – with simple blood draws which can enable repeat measurements – with the goal of dramatically improving heart failure patient management.
If I knew precisely what my patient’s circulating blood and/or plasma volume was, it would change the way I practice medicine in the ICU, particularly in situations where it is hard to estimate, for example in cardiac surgery and sepsis patients.
News and Announcements
FAST BioMedical News
FAST BioMedical Device Achieves Independent Validation by Premier Clinical Laboratory Testing Facility
Jim Dillon, Former St. Jude Medical Executive, Joins FAST BioMedical Board of Directors
FAST BioMedical Moves Wet Lab to 16 Tech
FAST BioMedical Establishes World-Recognized Heart Failure Medical Advisory Board
Dr. Gregory Brown Joins FAST BioMedical Board of Directors